

1/20




Figure 1

BEST AVAILABLE COPY

2/20




Figure 2

3/20




Figure 3

4/20





Figure 4

5/20

A



B





Figure 5

6/20




Figure 6


7/20

FIG 7

Primate $\gamma\delta$ cell number fold increase in response to increasing doses of Phosphostim


5

10




8/20

FIG 8

Serum cytokine (INF γ and TNF α) production in Phosphostim treated primates

9/20


FIG 9A



10/20



FIG9B

5



11/20



FIG 10



BEST AVAILABLE COPY

12/20



FIG 11



BEST AVAILABLE COPY

13/20



FIG 12



BEST AVAILABLE COPY

14/20

FIG 13



BEST AVAILABLE COPY

15/20

FIG 14A




FIG 14B




FIG 15
In vivo tumor development

5


10

786-O tumor

15

20

25




17/20

FIG 16


In vivo BrHPP stimulation and gdT cell proliferation

5



BEST AVAILABLE COPY

18/20


FIG 17**In vivo BrHPP stimulation and gdT cell proliferation**

5

BEST AVAILABLE COPY

FIG 18
Long-term anti-tumoral activity

5



20/20

FIG 19
Gamma delta anti-tumoral activity

